Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study (Q35998470)

11 August 2017

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study (English)

1 reference

11 August 2017

1 reference

1 reference

ChEBI release 2020-05-28

1 reference

D Strumberg

1

1 reference

11 August 2017

M E Scheulen

2

1 reference

11 August 2017

B Schultheis

3

1 reference

11 August 2017

H Richly

4

1 reference

11 August 2017

A Frost

5

1 reference

11 August 2017

M Büchert

6

1 reference

11 August 2017

O Christensen

7

1 reference

11 August 2017

M Jeffers

8

1 reference

11 August 2017

R Heinig

9

1 reference

11 August 2017

O Boix

10

1 reference

11 August 2017

K Mross

11

1 reference

11 August 2017

language of work or name

English

0 references

publication date

8 May 2012

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

106

1 reference

11 August 2017

11

1 reference

11 August 2017

1722-1727

1 reference

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

Evolving treatment of advanced colorectal cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

Global cancer statistics, 2002

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364125

23 September 2018

Identifiers

DOI

10.1038/BJC.2012.153

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

PubMed publication ID

22568966

1 reference